{"protocolSection": {"identificationModule": {"nctId": "NCT00189228", "nctIdAliases": ["NCT00201097"], "orgStudyIdInfo": {"id": "UNMSCOR"}, "secondaryIdInfos": [{"id": "R01HL044253", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01HL044253"}], "organization": {"fullName": "University of New Mexico", "class": "OTHER"}, "briefTitle": "Immune Dysfunction in Allergic Asthma", "officialTitle": "Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma"}, "statusModule": {"statusVerifiedDate": "2019-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-09"}, "primaryCompletionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-10", "studyFirstSubmitQcDate": "2005-09-10", "studyFirstPostDateStruct": {"date": "2005-09-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-07-23", "resultsFirstSubmitQcDate": "2019-09-26", "resultsFirstPostDateStruct": {"date": "2019-09-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-09-26", "lastUpdatePostDateStruct": {"date": "2019-09-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Mark Schuyler", "investigatorTitle": "Professor of Medicine", "investigatorAffiliation": "University of New Mexico"}, "leadSponsor": {"name": "University of New Mexico", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.", "detailedDescription": "Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "xolair", "type": "EXPERIMENTAL", "description": "This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.", "interventionNames": ["Drug: Xolair"]}], "interventions": [{"type": "DRUG", "name": "Xolair", "description": "Patients are administered Xolair", "armGroupLabels": ["xolair"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of the Response Curve. Final Values Are Derived From ELISA Units and the Serum Dilution", "description": "Asthma and control patients are immunized with KLH. Mean levels of anti-KLH antibody as described above. This is measured by ELISA and expressed as ELISA units which are derived by dilution of serum samples until the result falls on a linear portion of the response curve. Final values are derived from ELISA units and the serum dilution", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nMild asthma, adults -\n\nExclusion Criteria:\n\nchildren. on inhaled or systemic steroids\n\n-", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mark Schuyler, MD", "affiliation": "UNM HSC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "UNM HSC", "city": "Albuquerque", "state": "New Mexico", "zip": "87131", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "No events prior to the study", "recruitmentDetails": "Recruitment from the University community", "groups": [{"id": "FG000", "title": "Xolair", "description": "This is not a drug study examining differences of therapeutic outcomes. This is an open label, non randomized single dose level study in which patients will be treated for 85 days with rhuMAB-E25 (Xolair) and followed for a total of 300 days. The dose of Xolair is determined by the patient's total serum IgE and body weight and is administered subcutaneously every 2 or 4 weeks. Outcome is serum anti-KLH antibody (immunoglobulin classes)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Xolair", "description": "This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "18"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of the Response Curve. Final Values Are Derived From ELISA Units and the Serum Dilution", "description": "Asthma and control patients are immunized with KLH. Mean levels of anti-KLH antibody as described above. This is measured by ELISA and expressed as ELISA units which are derived by dilution of serum samples until the result falls on a linear portion of the response curve. Final values are derived from ELISA units and the serum dilution", "populationDescription": "Anti-KLH antibody levels of the groups (asthmatics treated with Xolair and placebo) were compared. Both parametric and non parametric statistical techniques were used. There were no differences between the groups.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units of anti-KLH antibody", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Xolair", "description": "This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18", "spread": "2"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "This is not a drug study.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.01", "statisticalMethod": "t-test, 2 sided", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Xolair", "description": "This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 0, "otherNumAtRisk": 18}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Mark Schuyler", "organization": "University of New Mexico Health Sciences Center", "email": "mschuyler@salud.unm.edu", "phone": "5059254197"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Pathological", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}